1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Paratus Digital Health Accelerator is sponsored by BARDA. Accelerator program for digital health solutions aligned with health security mission. Preliminary applications reviewed, with full proposals by invitation only.
Get alerted about grants like this
Save a search for “BARDA” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Paratus Digital Health Accelerator — Non-dilutive funding Learn more about Paratus — the BARDA Accelerator Network Hub for Digital Health. Click to explore opportunities... Learn more about Paratus — the BARDA Accelerator Network Hub for Digital Health.
Click to explore opportunities... Log in to our member portal Paratus Digital Health Accelerator — Non-dilutive Funding Providing non-dilutive funding awards for proof-of-concept studies that support the development, evaluation and validation of wearable biosensors for medical countermeasures, focusing on the detection or monitoring of emerging infectious diseases within BARDA's mission space.
We invite startups and university-backed projects to apply for non-dilutive funding awards up to $200,000. This funding supports proof-of-concept studies supporting the development, evaluation or validation of innovative digital health solutions aligned with the Center for the Biomedical Advanced Research and Development Authority’s (BARDA) mission to enhance pandemic preparedness and health security.
The Paratus Digital Health Accelerator -BARDA Accelerator Network Hub for Digital Health provides funding and support services to help entrepreneurs with the development of the clinical, technical and business elements of their product and company. Uniquely, Paratus is able to connect innovators with study sites to support their solutions. Complete the preliminary application by January 15, 2026.
Selected applicants will be invited to submit full proposals, including milestones and budgets, by February 2026. Notification of acceptance The first round of awards will be announced in June 2026. Non-dilutive funding awards Milestone-based funding and program services begin in summer 2026.
Non-dilutive funding opportunities Across these areas, we are interested in digital health solutions that can support preparedness, health readiness and mobilization.
Examples include, but are not limited to: Wearable and minimally invasive biosensing technologies to detect early physiological or biochemical signatures of diseases such as influenza, other infectious diseases and chemical, biological, and nuclear (CBRN) threats, enabling earlier diagnosis and intervention.
Edge analytics, signal fusion and anomaly-detection capabilities that leverage data from wearables and other distributed sensors to provide timely, reliable insights for triage, exposure alerts, and clinical decision support. Interoperable and secure data integration platforms that enable ingestion, standardization and privacy-preserving exchange of wearable-derived data across clinical, public health and emergency response systems.
Discovery, validation and application of digital biomarkers and predictive models that use longitudinal physiological, behavioral and contextual data to identify individuals at highest risk of deterioration, guide countermeasure deployment, and inform treatment strategies.
Resilient deployment platforms for large-scale wearable monitoring that support rapid provisioning, calibration and sustained operation of sensors in austere or resource-limited settings, with robust logistics, connectivity and power solutions. Funding between $50,000-$200,000 and projects that range from six to 12 weeks.
Advance technologies currently in development to the next milestone and value inflection points Engage a study site to complete validation work Increase access, reduce cost and more rapidly deploy medical countermeasures Advance platforms in development to improve clinical research and clinical care coordination We will evaluate submissions with the following criteria in mind: Ability to clearly articulate the problem statement Demonstration of the quality, feasibility and scalability of proposed solution Differentiation of solution within the competitive landscape Capability of participant to develop and execute the solution We recognize that reaching the next inflection point requires answering key questions for many companies, ranging from clinical and business-related to product- and platform-specific.
Paratus has both expert mentors and study site partners available to help answer these questions. Each engagement should be detailed as part of the full proposal, if invited. Explore study pathway examples .
Study-site matching: Work with health systems or other established partners We have an established group of partners that will accept studies as part of the Paratus programs. This group of health system partners can be leveraged to conduct specific studies. If you are a company with specific needs, we can help you find a match and take your solution to this network; the cost for engagement will be incorporated into the study’s funding.
Benefits of participation Startups and studies will receive non-dilutive funding to complete a time-bound development, evaluation or validation study around their concept.
Additional benefits of participation include the following: Receive project management support and regular mentoring from subject matter experts over the award duration Receive mentorship from industry leaders and subject matter experts Gain exposure to the MATTER community Present to potential investors, partners and clients We’re seeking entrepreneurs and university-backed researchers who are developing digital health solutions that will empower the nation to prepare for and respond to health security threats and improve the continuum of clinical care.
This global call for solutions is open to startups from across the innovation ecosystem with an established proof of concept, evidence of product-market fit and business model potential. This program is conducted virtually. See the full Terms and Conditions .
Paratus Information Session for Non-dilutive Funding Gain of function research This funding opportunity does not support gain of function research or research that involves the manipulation of pathogens resulting in potential gain of function. Proposals will be evaluated for the appropriate use of strain(s) in proposed studies.
Explore more opportunities with Paratus The Paratus Digital Health Accelerator program is seeking to accelerate digital health tools that enhance preparedness and response to public health emergencies due to: 1. Chemical, biological, radiological and nuclear (CBRN) threats 3. Emerging infectious diseases At MATTER, we believe collaboration is the best way to improve healthcare.
The MATTER collaborative includes more than 1,000 current and alumni startups from around the world, working together with dozens of hospitals and health systems, universities and industry-leading companies to build the future of healthcare. Together we are accelerating innovation, advancing care and improving lives. For more information, visit matter.
health and follow @MATTERhealth. The BARDA Accelerator Network The BARDA Accelerator Network aims to provide comprehensive support to health security innovators, startups and BARDA portfolio companies through wrap-around accelerator services, technical and business/commercialization expertise, and resources. The network will facilitate the rapid development, evaluation, validation and commercialization of medical countermeasures.
Stay up to date on MATTER news, programs and more. 222 W. Merchandise Mart Plaza, Suite 228, Chicago, IL 60654
Based on current listing details, eligibility includes: Startups and university-backed researchers developing digital health solutions addressing pandemic preparedness and health security threats, with established proof of concept and evidence of product-market fit. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $50,000 - $200,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is January 15, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.